Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18

Virology Journal

Volumn 8, Issue , 2011, Pages

  Zhao, Li ^a   Liu, Binlei ^b   Ren, Jiao ^a   Feng, Jing ^a   Pang, Zheng ^a   Gao, Jian ^a   Zhang, Hui ^a   Tan, Wenjie ^a   Tian, Houwen ^a   Ruan, Li ^a  

^a National Institute for Communicable Disease Control and Prevention   (China)

^b CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; PROTEIN E6; PROTEIN E7; RECOMBINANT VACCINE; VACCINIA VACCINE; DNA BINDING PROTEIN; DRUG CARRIER; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; E7 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 18; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN; WART VIRUS VACCINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; MOUSE; NONHUMAN; UTERINE CERVIX CANCER; VACCINIA VIRUS; ANIMAL; C57BL MOUSE; CARCINOMA; CD8+ T LYMPHOCYTE; DISEASE MODEL; GENE VECTOR; GENETICS; IMMUNOLOGY; MACACA MULATTA; RODENT DISEASE; TREATMENT OUTCOME; TUMOR CELL LINE;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; MACACA MULATTA; MUS; VACCINIA VIRUS;

ANIMALS; CARCINOMA; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DRUG CARRIERS; FEMALE; GENETIC VECTORS; MACACA MULATTA; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; RODENT DISEASES; TREATMENT OUTCOME; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 79958770850     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-302     Document Type: Article

References (29)

1. Estimates of the worldwide incidence of 25 major cancers in 1990. DM Parkin P Pisani J Ferlay, Int J Cancer 1999 80 827 841 10.1002/(SICI)1097- 0215(19990315)80:6<827::AID-IJC63.0.CO;2-P 10074914 (Pubitemid 29108856)
2. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. JM Walboomers MV Jacobs MM Manos FX Bosch JA Kummer KV Shah PJ Snijders J Peto CJ Meijer N Munoz, J Pathol 1999 189 12 19 10.1002/(SICI)1096- 9896(199909)189:1<12::AID-PATH4313.0.CO;2-F 10451482 (Pubitemid 29406813)
3. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. GM Clifford JS Smith M Plummer N Munoz S Franceschi, Br J Cancer 2003 88 63 73 10.1038/sj.bjc.6600688 12556961
4. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. JT Schiller X Castellsague LL Villa A Hildesheim, Vaccine 2008 26 Suppl 10 53 61 18847557
5. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. K Munger WC Phelps V Bubb PM Howley R Schlegel, J Virol 1989 63 4417 4421 2476573 (Pubitemid 19229441)
6. Human papillomavirus type 16 E6-induced degradation of E6TP1 correlates with its ability to immortalize human mammary epithelial cells. Q Gao L Singh A Kumar S Srinivasan DE Wazer V Band, J Virol 2001 75 4459 4466 10.1128/JVI.75.9.4459-4466.2001 11287601 (Pubitemid 32410164)
7. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. K Munger JR Basile S Duensing A Eichten SL Gonzalez M Grace VL Zacny, Oncogene 2001 20 7888 7898 10.1038/sj.onc.1204860 11753671 (Pubitemid 33135315)
8. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. S Peng C Trimble L He YC Tsai CT Lin DA Boyd D Pardoll CF Hung TC Wu, Gene Ther 2006 13 67 77 10.1038/sj.gt.3302607 16107858 (Pubitemid 41823853)
9. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. S Peng H Ji C Trimble L He YC Tsai J Yeatermeyer DA Boyd CF Hung TC Wu, J Virol 2004 78 8468 8476 10.1128/JVI.78.16.8468-8476.2004 15280455 (Pubitemid 39025112)
10. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. ME Ressing A Sette RM Brandt J Ruppert PA Wentworth M Hartman C Oseroff HM Grey CJ Melief WM Kast, J Immunol 1995 154 5934 5943 7538538
11. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. FX Bosch MM Manos N Munoz M Sherman AM Jansen J Peto MH Schiffman V Moreno R Kurman KV Shah, J Natl Cancer Inst 1995 87 796 802 10.1093/jnci/87.11. 796 7791229
12. The immunological effect of a Hepatitis a-vaccinia recombinant virus (VMS11HAV25) in human. KJ Guo L Ruan XJ Wang Y Yi CB Liu YH Ren YC Zhang XH Liu SJ Gao JW Yang JM Ju, 1992 2 8 137 140
13. A preliminary study on the immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen. S Gu T Huang Y Miao L Ruan Y Zhao C Han Y Xiao J Zhu H Wolf, Chin Med Sci J 1991 6 241 243 1667485
14. Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Q Fang L Yang W Zhu L Liu H Wang W Yu G Xiao P Tien L Zhang Z Chen, Virology 2005 335 242 251 10.1016/j.virol.2005.02.014 15840523 (Pubitemid 40544913)
15. Vaccinia virus proteins activate human dendritic cells to induce T cell responses in vitro. S Agrawal S Gupta A Agrawal, Vaccine 2009 27 88 92 10.1016/j.vaccine.2008.10.031 18977270
16. Identification specific T lymphocyte epitopes on E6 protein of human papillomavirus type 18 in mice. L Zhao J Ren J Feng Z Pang Z ZHang W Tan H Tian L Ruan, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2010 24 6 406 408 21604559
17. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. KY Lin FG Guarnieri KF Staveley-O'Carroll HI Levitsky JT August DM Pardoll TC Wu, Cancer Res 1996 56 21 26 8548765 (Pubitemid 26010379)
18. The recombinant vaccinia viruses expressing HPV type 16 wild or mutant E7 protein elicit immunity against tumor cells in mice. H Zhi L Han J Ren HW Tian WF Lao Y Liang L Ruan, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2001 15 222 225 11986689
19. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. MC Feltkamp HL Smits MP Vierboom RP Minnaar BM de Jongh JW Drijfhout J ter Schegget CJ Melief WM Kast, Eur J Immunol 1993 23 2242 2249 10.1002/eji.1830230929 7690326 (Pubitemid 23265889)
20. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. JO Lee AA Russo NP Pavletich, Nature 1998 391 859 865 10.1038/36038 9495340 (Pubitemid 28157656)
21. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. ME Boursnell E Rutherford JK Hickling EA Rollinson AJ Munro N Rolley CS McLean LK Borysiewicz K Vousden SC Inglis, Vaccine 1996 14 1485 1494 10.1016/S0264-410X(96)00117-X 9014288 (Pubitemid 27023490)
22. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. S Dalal Q Gao EJ Androphy V Band, J Virol 1996 70 683 688 8551603 (Pubitemid 26028982)
23. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro. S Nakagawa S Watanabe H Yoshikawa Y Taketani K Yoshiike T Kanda, Virology 1995 212 535 542 10.1006/viro.1995.1511 7571423
24. Modification of HPV type 16 E6 and E7 genes, and analysis of stability and immunogenicity of the modified proteins. H Zhi L Han J Ren H Tian W Luo Y Liang L Ruan, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2002 16 124 127 12196821
25. Constuction of the replication -deficient recombinant vaccinia virus expressing HPV58 L1 and L2 capsid proteins. HW Tian LQ Han J Ren WF Luo ZH Lu L Ruan, Chinese Journal of Virology 2002 18 3 222 226
26. Constuction of non-replicating recombinant vaccinia virus expressing human papillomavirus 16E6/E7 fusion protein and study of its immunogenicity and antitumor response. HW Tian J Ren W Huang JT Fan L Zhao L Ruan, Chinese Journal of Virology 2006 22 5 358 363
27. Cutting edge: rapid in vivo killing by memory CD8 T cells. DL Barber EJ Wherry R Ahmed, J Immunol 2003 171 27 31 12816979 (Pubitemid 36745269)
28. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. C McCarthy SJ Youde S Man, Int J Cancer 2006 118 2514 2521 10.1002/ijc.21643 16353149
29. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. J Yan K Harris AS Khan R Draghia-Akli D Sewell DB Weiner, Vaccine 2008 26 5210 5215 10.1016/j.vaccine. 2008.03.069 18455277